NCT02446093Phase 2Unknown

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Study sponsor: Candel Therapeutics, Inc. · CADL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-12Estimated

Enrollment · participants54Estimated

Source updated2024-01-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Borderline Resectable Pancreatic Adenocarcinoma

Treatments or interventions studied

Aglatimagene besadenovecBiologicalAlso known as CAN-2409, AdV-tk

Primary outcomes · main study measures

measure: Safety grade by CTCAE version 4.0; description: Frequency of adverse events.; timeFrame: From the time of CAN-2409 administration to 30 days after the last dose of valacyclovir.; measure: Survival Rate; description: All eligible subjects will be followed for at least 2 additional years from the completion of primary treatment window.; timeFrame: 24 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history